ReviewWorld journal of gastroenterology2014
Helicobacter pylori eradication for preventing gastric cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Risk Factors for Gastric Cancer: A Systematic ReviewAsian Pacific journal of cancer prevention : APJCP · 2018Pooled it
- Integration of single-cell regulon atlas and bulk RNA-seq for individualized prognostic prediction in stomach adenocarcinoma.iScience · 2026Article
- Using Caprylic Acid for the Prevention and Treatment ofMetabolites · 2025Review
- Knowledge and practice of early gastric cancer screening among adults aged ≥ 45 years in China: a cross-sectional study.BMC public health · 2024Article
- Association betweenBMJ open gastroenterology · 2024Article
- Article
- Association between rs3761548 polymorphism ofMolecular biology research communications · 2024Article
- Histopathological Findings in Adult Patients With Dyspepsia and Their Association With Helicobacter pylori Infection.Cureus · 2023Article
- Stomach cancer burden in China: Epidemiology and prevention.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Tight junctions: from molecules to gastrointestinal diseases.Tissue barriers · 2023Article
- Prevention of malignant digestive system tumors should focus on the control of chronic inflammation.World journal of gastrointestinal oncology · 2023Review
- Antibiotic Resistance ofMedicina (Kaunas, Lithuania) · 2022Article
- The Effects of Risk Factors on One- and Five-Year Survival of Patients with Gastric Cancer in Isfahan in 2016.Middle East journal of digestive diseases · 2022Article
- Article
- Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets.Cancers · 2021Review
- Review
- NF-kB-dependent activation of STAT3 by H. pylori is suppressed by TFF1.Cancer cell international · 2021Article
- Association analysis between SNPs in LATS1 and LATS2 and non-cardia gastric cancer.BMC gastroenterology · 2020Article
- The trends of mortality and years of life lost of cancers in urban and rural areas in China, 1990-2017.Cancer medicine · 2020Article
- Gastric Mucosa-Associated Microbial Signatures of Early Gastric Cancer.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) infection is a major risk factor for gastric cancer (GC) development, which is one of the most challenging malignant diseases worldwide with limited treatments. In the multistep pathogenesis of GC, H. pylori infection slowly induces chronic active gastritis, which progresses through the premalignant stages of atrophic gastritis, intestinal metaplasia, and dysplasia, and then finally to GC. Although eradication of H. pylori is a reasonable approach for the prevention of GC, there have been some contradictory reports, with only some long-term follow-up data showing efficacy of this approach. The inconsistencies are likely due to the insufficient number of participants, relatively short follow-up periods, poor quality of study designs, and the degree and extent of preneoplastic changes at the time of H. pylori eradication. This review analyzes recent high-quality studies to resolve the discrepancies regarding the eradication of H. pylori for GC prevention. The relationship between H. pylori eradication and GC/precancerous lesions/metachronous GC is examined, and the cost-effectiveness of this strategy in the prevention of GC is assessed. Although it is assumed that eradication of H. pylori has the potential to prevent GC, the feasibility and appropriate timing of this strategy for cancer prevention remain to be determined. As a result, additional well-designed trials with longer follow-up periods are needed to clarify this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.